Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q4 FY2026 Earnings Presentation
25 slides from Aurobindo Pharma's earnings presentation, May 21, 2026
Slide 1: Cover letter to stock exchanges
May 21, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI -400 051 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Company Cod
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q4FY26
Aurobindo Pharma Limited Earnings Presentation Q4FY26
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q4FY26 Business & Financial Highlights 11 Update on Biosimilars 18 Financial Summary 13 21 Filings Snapshot 3
Slide 5: Q4FY26 Business & Financial Highlights
Q4FY26 Business & Financial Highlights 4
Slide 6: Key Financial Highlights of the Quarter
Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q4FY26 ₹ 8,853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 55
Slide 7: Business Highlights – Q4FY26
Business Highlights – Q4FY26 Revenue of ₹8,853 crores with 5.6% growth YoY, driven by strong Europe performance coupled with stable US performance despite no transient product sales Reported EBITDA of ₹1,801 crores with a margin of 20.3%, driven by stable gross margins and operating efficiencies Net
Slide 8: Quarterly Performance – Q4FY26
Quarterly Performance – Q4FY26 Revenue (Rs Crore) EBITDA (Rs Crore) 8,853 8,646 1,792 1,801 1,773 8,382 8,286 7,979 1,678 7,868 1,628 1,603 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 PAT (Rs Crore) Cash flows before dividend and buyback ($ Mn) 131 903 910 921
Slide 9: Consolidated Business Performance
Consolidated Business Performance Q-o-Q ₹ Crores Q4FY26 Q4FY25 Y-o-Y (%) Q3FY26 FY26 FY25 Y-o-Y (%) (%) USA 3,543 4,072 -13.0% 3,739 -5.2% 14,408 14,816 -2.7% Europe 2,795 2,147 30.2% 2,703 3.4% 10,315 8,356 23.4% Growth Markets* 980 786 24.7% 865 13.3% 3,499 3,180 10.0% ARV 328 308 6.4% 376 -12.8%
Slide 10: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 470 • US revenue in Q4FY26 accounted for 40.0% of 420 387 consolidated revenue. The Q-o-Q decline was primarily driven by seasonality impact. The base business remained stable despite lower transient
Slide 11: Revenue Break-up by Business
Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Crore) 1,208 261 107 261 1,069 236 97 91 963 42 36 36 Q4FY25 Q3FY26 Q4FY26 Q4FY25 Q3FY26 Q4FY26 Q4FY25 Q3FY26 Q4FY26 Q4FY25 Q3FY26 Q4FY26 Europe business posted ARV business continued API business revenues incre
Slide 12: Update on Biosimilars
Update on Biosimilars 11
Slide 13: CuraTeQ Biologics – Building a Global Biosimilars Company
CuraTeQ Biologics – Building a Global Biosimilars Company Our Progress Drivers • Total Addressable Market in the Approvals in Regulated Markets • EEA: Zefylti, Dyrupeg, Dazublys The Opportunity next decade USD 50 Bn • UK: Zefylti, Dyrupeg, Dazublys, • Over 30 leading biologics, each generating USD 1
Slide 14: Q4 Key Highlights and Upcoming Milestones
Q4 Key Highlights and Upcoming Milestones • Successful Omalizumab Phase 3 Completion: Successfully met all primary endpoints in a study conducted in chronic spontaneous urticaria patients enabling planned EMA and FDA filings by end of Q2 2026 • Denosumab Filing: Denosumab biosimilar filing as planne
Slide 15: CuraTeQ's Biosimilars Pipeline Status
CuraTeQ’s Biosimilars Pipeline Status Brand Name Product Name Therapeutic Segment Clinical Filing Approval Launch DYRUPEG Pegfilgrastim EMA, MHRA, HC ZEFYLTI Filgrastim EMA, MHRA BEVQOLVA Bevacizumab Oncology Phase 3 ongoing MHRA, HC DAZUBLYS Trastuzumab EMA, MHRA, CDSCO FUGEVY# | FILV
Slide 16: Key Next-Wave Products to Sustain Momentum
Key Next-Wave Products to Sustain Momentum Global Market Product Key Indications 2025 Revenue (est.) Opportunity (est.)* by Code 2030 Plaque Psoriasis, Psoriatic Arthritis, Ankylosing BP31 $6.7B $9.5B Spondylitis BP36 Atopic Dermatitis, Asthma $13.1B $22.0B BP30 Multiple Myeloma $14.4B $16.0B Ulcera
Slide 17: CuraTeQ by 2030 poised to be a leading biosimilars player
Curateq by 2030 is poised to be one of the leading biosimilars players with a strong focus on oncology and a growing focus on immunology segments At least two oncology A total of seven to eight FDA success can translate and two immunology One IL inhibitor and one 2030 marketed products in EU, UK int
Slide 18: TheraNym – Our Foray into Biologics Contract Manufacturing
TheraNym – Our Foray into Biologics Contract Manufacturing • TheraNym Unit 1 Update: 60 kL integrated mammalian cell culture facility commissioning to be fully completed by end-2026, as planned • Strengthening Collaboration with MSD: TheraNym executed an additional product schedule with Merck Sharp
Slide 19: Financial Summary
Financial Summary 18
Slide 20: Summary Consolidated Profit & Loss Statement
Summary Consolidated Profit & Loss Statement YoY Chg. QoQ Chg. YoY Chg. Rs Cr Q4FY26 Q4FY25 Q3FY26 FY26 FY25 (%) (%) (%) Revenue from Operations 8,853 8,382 5.6% 8,646 2.4% 33,653 31,724 6.1% Gross Profit 5,424 4,954 9.5% 5,165 5.0% 20,165 18,697 7.8% Gross Margin 61.3% 59.1% 216 bps 59.7% 153 bps 5
Slide 21: Debt Profile
Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-22 Mar-23 Mar-24 Mar-25 Mar-26 Closing Rate (INR/USD) 75.793 82.170 83.405 85.475 94.835 963 930 884 843 786 809 Fx Loan restated in INR 2,223 4,638 3,994 5,883 6,709 Rupee Loan 150 224 2,324 2,065 964 228 182 185 117 99 84 Gross Debt 2,373 4,
Slide 22: Filing Snapshot
Filing Snapshot 21
Slide 23: US ANDA Filings Snapshot as on 31st March 2026
US ANDA Filings Snapshot as on 31st March 2026 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^^ CNS 166 34.3 Aurobindo (Excl. Specialty & 800 728 600 554 Specialty & Injectables 300 700 ARV 30 1.5 600 500 250 500 200 174 Injectables) 400 400 150 48.2 300 300 CVS 124 200 125 200 102 100
Slide 24: Global Regulatory Filing Details
Global Regulatory Filing Details As at As at As at As at As at Category Geography Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 US* 727 774 830 861 888 Europe** 3,580 3,751 3,642 3,933 4,344 Formulations SA** 370 368 403 423 397 Canada 214 240 261 269 282 Total 4,891 5,133 5,136 5,486 5,911 US 261 276 291 309
Slide 25: Thank You
Thank You Digitally signed by ADI REDDY For more information, contact: ir@aurobindo.com BADDIGAM Date: 2026.05.21 20:26:10 +05'30' Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1211 2424